Advanced in Epithelial-Myoepithelial Carcinoma

Dr. Hatem H. Soliman

Hematology Oncology | Hematology | Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Epithelial-Myoepithelial Carcinoma
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hatem Soliman is a Hematologist Oncology specialist and a Hematologist in Tampa, Florida. Dr. Soliman is rated as an Advanced provider by MediFind in the treatment of Epithelial-Myoepithelial Carcinoma. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Breast Cancer in Men, and Triple-Negative Breast Cancer. Dr. Soliman is currently accepting new patients.

His clinical research consists of co-authoring 106 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Epithelial-Myoepithelial Carcinoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Diagnostic test
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Biological
Study Drugs: PVX-410, Durvalumab, Hiltonol
Study Phase: Phase 1
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Biological, Drug
Study Drugs: Talimogene Laherparepvec, Paclitaxel
Study Phase: Phase 1/Phase 2
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Biological, Drug, Procedure
Study Drugs: Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy
Study Phase: Early Phase 1
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Radiation, Drug
Study Drug: Nivolumab
Study Phase: Phase 1
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
Enrollment Status: Unknown
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Device
Study Drugs: tavokinogene telseplasmid, Pembrolizumab, nab paclitaxel
Study Phase: Phase 2
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Biological, Procedure, Other
Study Drugs: Interferon-gamma (IFN-?), Paclitaxel, Trastuzumab
Study Phase: Phase 1/Phase 2
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial With Safety Run-in of Neoadjuvant Therapy With an Aromatase Inhibitor in Combination With Durvalumab (MEDI4736) in Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
A Phase II Trial With Safety Run-in of Neoadjuvant Therapy With an Aromatase Inhibitor in Combination With Durvalumab (MEDI4736) in Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
Enrollment Status: Terminated
Publish Date: May 31, 2022
Intervention Type: Drug
Study Drugs: Durvalumab, Anastrozole, Letrozole, Exemestane
Study Phase: Phase 2
The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Enrollment Status: Completed
Publish Date: January 21, 2022
Intervention Type: Drug
Study Drugs: Tamoxifen, Ribociclib, Goserelin
Study Phase: Phase 1
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Enrollment Status: Terminated
Publish Date: February 04, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study of PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Before and After Neoadjuvant Chemotherapy
Pilot Study of PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Before and After Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: December 04, 2020
Intervention Type: Biological, Diagnostic test
Study Phase: Early Phase 1
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Other, Drug
Study Phase: Early Phase 1
View 19 Less Clinical Trials

106 Total Publications

Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis.
Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis.
Journal: Oncology and therapy
Published: August 01, 2025
Similar Doctors
Distinguished in Epithelial-Myoepithelial Carcinoma
Dr. Kedar S. Kirtane
Hematology Oncology
Distinguished in Epithelial-Myoepithelial Carcinoma
Dr. Kedar S. Kirtane
Hematology Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English, Marathi
See accepted insurances
Accepting New Patients
Offers Telehealth

Kedar Kirtane is a Hematologist Oncology provider in Tampa, Florida. Dr. Kirtane is rated as a Distinguished provider by MediFind in the treatment of Epithelial-Myoepithelial Carcinoma. His top areas of expertise are Laryngeal Cancer, Glioma, Epithelial-Myoepithelial Carcinoma, and Throat Cancer. Dr. Kirtane is currently accepting new patients.

Distinguished in Epithelial-Myoepithelial Carcinoma
Dr. Christine H. Chung
Oncology
Distinguished in Epithelial-Myoepithelial Carcinoma
Dr. Christine H. Chung
Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

4101 Jim Walter Blvd, 
Tampa, FL 
 (8.7 miles away)
888-860-2778
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Christine Chung is an Oncologist in Tampa, Florida. Dr. Chung is rated as a Distinguished provider by MediFind in the treatment of Epithelial-Myoepithelial Carcinoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, Epithelial-Myoepithelial Carcinoma, Salivary Gland Tumors, and Thyroidectomy. Dr. Chung is currently accepting new patients.

Guilherme Rabinowits
Advanced in Epithelial-Myoepithelial Carcinoma
Dr. Guilherme Rabinowits
Oncology | Hematology Oncology | Hematology
Advanced in Epithelial-Myoepithelial Carcinoma
Dr. Guilherme Rabinowits
Oncology | Hematology Oncology | Hematology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Guilherme Rabinowits is an Oncologist and a Hematologist Oncology provider in Tampa, Florida. Dr. Rabinowits is rated as a Distinguished provider by MediFind in the treatment of Epithelial-Myoepithelial Carcinoma. His top areas of expertise are Merkel Cell Carcinoma, Tongue Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Neuroendocrine Tumor. Dr. Rabinowits is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Soliman's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile